AlphAIAlphAI — Financial news for AI agents
fool.comOCT 293 min read$ALNY

Alnylam (ALNY) Q3 2026 Earnings Call Transcript

Alnylam (ALNY) reported Q3 2026 revenue of $1.46B, up 17% YoY, driven by TTR franchise growth. AMVUTTRA sales rose 65% YoY to $1.13B. Guidance for TTR product sales was lowered to the range of $4.2B-$4.5B. Management cited Medicare Advantage policy changes and 340B reimbursement adjustments as risks. TRITON-CM study enrollment target was expanded to 2,250 patients.

Original reporting
fool.com
Published Oct 29, 2026, 4:53 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 29, 2026, 5:19 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
Alnylam (ALNY) Q3 2026 Earnings Call Transcript — source image
Source · fool.com
Decision brief

The 30-second read

$ALNYBearishHigh
01

Why it matters

The earnings release provides fresh quantitative data and forward guidance, creating immediate trading relevance.

02

Market read

First‑report earnings with material numbers and guidance, likely to move the stock in the short term.

03

What to watch

Potential upside from upcoming Huntington's disease trial data and possible new collaborations.

Relevance 8/10Novelty 8/10Timing: after market close

Background

Alnylam Pharmaceuticals presented its Q3 2026 earnings, highlighting revenue growth, product performance, and guidance.

Company-level read

Ticker impact

$ALNYBearishHigh confidence
Context

Q3 2026 earnings call disclosed $1.46B revenue, 17% YoY growth, and full‑year TTR product revenue guidance of $4.2‑$4.5B.

Expected impact

likely modest downside as investors price in lower‑end guidance and Medicare Advantage restrictions.

Evidence & confidence

The company reported strong sales growth yet trimmed outlook and highlighted payer‑risk, which historically triggers short‑term price pressure.

Market effects

Sector

Biotech sector may see heightened scrutiny on payer‑risk for rare‑disease therapies.

Regional

U.S. biotech stocks could face slight pressure in the near term.

Global

Limited; impact confined to investors tracking RNAi therapeutics.

Counterpoint

What could challenge this read

Despite payer‑risk comments, the strong product revenue growth could support upside if guidance is revised upward later.

Key entities

  • company
    Alnylam Pharmaceuticals

    US‑listed biotech firm (ticker ALNY) reporting Q3 2026 results.

Read at source← All news

StoryAlnylam Q3 2026 earnings beat, expands nucresiran trial and reaffirms FY‑26 outlook

Also covered by

4 outlets

Related articles

OCT 29
$ALNYMed

Alnylam Pharmaceuticals Q3 Earnings Call Highlights

Alnylam Pharmaceuticals reported that AMVUTTRA has access for 99% of covered lives, with 90% of patients within 10 miles of treatment. The company is monitoring a proposed CMS rule that could reduce Medicare reimbursement for 340B drugs, which represents a meaningful portion of its business. UnitedHealth implemented a restrictive policy for AMVUTTRA, potentially delaying access for new patients.

finance.yahoo.com2 min
OCT 29
$ALNYMed

Alnylam Sinks 19% as It Expands Nucresiran Heart Trial Again, Citing “A High Level of Conviction”

Alnylam Pharmaceuticals (ALNY) shares fell 19% after expanding its nucresiran heart trial to 2,250 patients, citing confidence in positive results. Despite 52% product revenue growth, concerns arise about nucresiran's benefit. Analysts expect revenue growth through 2028, driven by AMVUTTRA. Competitors like Pfizer (PFE) and BridgeBio (BBIO) may gain if nucresiran's data is weak.

finance.yahoo.com2 min
OCT 29
$ALNYHighAI 8/10

Alnylam Reports 17% Q3 Revenue Growth, Expands Nucresiran Trial And Advances RNAi Pipeline

Alnylam Pharmaceuticals (ALNY) reported Q3 2026 revenue growth of 16.7% to $1.458 billion, driven by a 52% increase in global net product revenue, primarily from its TTR franchise. Net income rose to $2.167 billion. The company expanded its Phase 3 study for nucresiran and presented promising early data for brezosiran in Huntington's disease. Alnylam also advanced its pipeline with mivelsiran and ALN-5288 for neurological diseases.

rttnews.com3 min
OCT 29
$ALNYMedAI 8/10

Alnylam Pharmaceuticals Shares Update About Phase 3 Nucresiran Study, Reaffirms FY26 Outlook

Alnylam Pharmaceuticals (ALNY) updated its Phase 3 TRITON-CM study for nucresiran, expanding enrollment to 2,250 patients. The company aims for a 2030 launch, viewing it as key to long-term growth. Alnylam reaffirmed its FY26 outlook: $4.7B-$5.1B in product revenue, $575M-$625M in collaboration revenue, and $2.7B-$2.8B in R&D/SG&A expenses. ALNY stock fell 17.89% to $190.71.

rttnews.com1 min